HUE035362T2 - Dermatological preparations containing heparan sulfate - Google Patents
Dermatological preparations containing heparan sulfate Download PDFInfo
- Publication number
- HUE035362T2 HUE035362T2 HUE13159487A HUE13159487A HUE035362T2 HU E035362 T2 HUE035362 T2 HU E035362T2 HU E13159487 A HUE13159487 A HU E13159487A HU E13159487 A HUE13159487 A HU E13159487A HU E035362 T2 HUE035362 T2 HU E035362T2
- Authority
- HU
- Hungary
- Prior art keywords
- heparan sulfate
- sulfate
- heparan
- concentration
- substance
- Prior art date
Links
- 229920002971 Heparan sulfate Polymers 0.000 title claims description 39
- 239000000203 mixture Substances 0.000 title description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000070928 Calligonum comosum Species 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000003795 desorption Methods 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 239000003957 anion exchange resin Substances 0.000 description 5
- 210000003651 basophil Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 4
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940083608 sodium hydroxide Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 102000002268 Hexosaminidases Human genes 0.000 description 1
- 108010000540 Hexosaminidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- -1 alkaline earth metal salt Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000001741 organic sulfur group Chemical group 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08169547 | 2008-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE035362T2 true HUE035362T2 (en) | 2018-05-02 |
Family
ID=41587870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13159487A HUE035362T2 (en) | 2008-11-20 | 2009-09-29 | Dermatological preparations containing heparan sulfate |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9440099B2 (https=) |
| EP (2) | EP2346573B1 (https=) |
| JP (3) | JP2012509289A (https=) |
| KR (1) | KR101669528B1 (https=) |
| DK (2) | DK2346573T3 (https=) |
| ES (2) | ES2650937T3 (https=) |
| HR (2) | HRP20140862T1 (https=) |
| HU (1) | HUE035362T2 (https=) |
| LT (1) | LT2679278T (https=) |
| NO (1) | NO2679278T3 (https=) |
| PL (2) | PL2346573T3 (https=) |
| PT (2) | PT2346573E (https=) |
| SI (2) | SI2679278T1 (https=) |
| WO (1) | WO2010057710A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2679278T1 (en) * | 2008-11-20 | 2018-02-28 | Laboratori Derivati Organici S.P.A. | Dermatological compositions comprising heparan sulphate |
| FR3000067B1 (fr) * | 2012-12-21 | 2016-05-13 | Oreal | Composes c-xylosides ,compositions et leur utilisation pour depigmenter la peau |
| MX2015015814A (es) | 2013-05-16 | 2016-06-02 | Agency Science Tech & Res | Sulfatos de heparán. |
| CN107249599A (zh) | 2014-11-19 | 2017-10-13 | 新加坡科技研究局 | 硫酸乙酰肝素用于皮肤修复和/或再生 |
| SG11201704086WA (en) * | 2014-11-19 | 2017-06-29 | Agency Science Tech & Res | Cosmetic use of heparan sulphate |
| ITUB20160156A1 (it) * | 2016-02-05 | 2017-08-05 | Laboratori Derivati Organici Spa | Composizioni comprendenti una miscela di glicosamminoglicani e loro uso in composizioni cosmetiche e dermatologiche |
| CN108329405B (zh) * | 2018-02-08 | 2020-06-23 | 黄石市典雅生物科技有限公司 | 一种树脂吸附状态下保护及纯化肝素钠的方法 |
| CN111909288B (zh) * | 2020-08-13 | 2021-09-03 | 山东辰龙药业有限公司 | 一种肝素钠的精制方法 |
| KR20220096932A (ko) | 2020-12-31 | 2022-07-07 | 주식회사 유연테크 | 분진제거와 제습기능이 결합된 제습 싸이크론 건조기 |
| US12059430B2 (en) | 2022-09-29 | 2024-08-13 | Adora Animal Health Corporation | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63150209A (ja) * | 1986-12-15 | 1988-06-22 | Kanebo Ltd | 皮膚化粧料 |
| IT1212143B (it) * | 1987-06-26 | 1989-11-08 | Crinos Industria Farmaco | Composizione ad attivita'tricogena. |
| JPH0696514B2 (ja) * | 1987-07-15 | 1994-11-30 | 鐘紡株式会社 | 皮膚化粧料 |
| JPH06104620B2 (ja) * | 1987-07-15 | 1994-12-21 | 鐘紡株式会社 | 皮膚化粧料 |
| DK505488D0 (da) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | Middel og anvendelse af samme |
| FR2643909B1 (fr) * | 1989-03-03 | 1993-01-22 | Bioetica Sa | Composition de base pour la preparation d'une composition cosmetique formant composition capillaire et composition cosmetique formant composition capillaire ainsi preparee, contenant de l'heparine ou de l'heparane sulfate |
| JPH03161416A (ja) * | 1989-11-21 | 1991-07-11 | Kanebo Ltd | 皮膚化粧料 |
| JP2931083B2 (ja) * | 1990-11-22 | 1999-08-09 | ポーラ化成工業株式会社 | 皮膚化粧料 |
| JPH05310548A (ja) * | 1992-05-13 | 1993-11-22 | Taisho Pharmaceut Co Ltd | 皮膚外用剤 |
| GB9318288D0 (en) * | 1993-09-03 | 1993-10-20 | Nycomed Imaging As | Improvements in or relating to contrast agents |
| SE9402531L (sv) * | 1994-07-19 | 1996-01-20 | Medicarb Ab | Sårläkningsmedel |
| JPH0899861A (ja) * | 1994-09-30 | 1996-04-16 | Kose Corp | 皮膚外用剤 |
| US5989874A (en) * | 1995-03-27 | 1999-11-23 | Tayca Corporation | Humectant, antistatic agent, dispersant and film-forming agent having polysaccharide as active principle, preparation process of polysaccharides, and Kliebsiella ocytoca TNM-3 strain |
| WO1997011096A1 (en) * | 1995-09-19 | 1997-03-27 | Seikagaku Corporation | Anti-inflammatory agent |
| US5935599A (en) * | 1996-10-28 | 1999-08-10 | The Board Of Trustees Of The University Of Illinois | Polymer-associated liposomes for drug delivery and method of manufacturing the same |
| JP3687277B2 (ja) * | 1997-06-10 | 2005-08-24 | サンスター株式会社 | 美白化粧料 |
| GB9913237D0 (en) * | 1999-06-08 | 1999-08-04 | K C L Enterprises Limited | Product |
| JP4754066B2 (ja) * | 2000-12-22 | 2011-08-24 | 株式会社林原生物化学研究所 | 抗関節障害剤 |
| JP2003171256A (ja) * | 2001-12-03 | 2003-06-17 | Nonogawa Shoji Kk | 皮膚外用剤 |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| US20070129430A1 (en) * | 2003-10-07 | 2007-06-07 | Satomi Miyata | Agent for enhancing the production of collagen, their preparation and use |
| DE102004036689A1 (de) * | 2004-07-28 | 2006-03-23 | Henkel Kgaa | Rückstandsarmer Deodorant- oder Antitranspirant-Stift auf Basis einer Öl-in-Wasser-Dispersion |
| WO2007044945A2 (en) * | 2005-10-13 | 2007-04-19 | Gu, Jennifer, L. | Mineral collagen chelates and methods of making and using same |
| JP2007254316A (ja) * | 2006-03-22 | 2007-10-04 | Seikagaku Kogyo Co Ltd | Ｈａマトリックス形成阻害剤 |
| JP4564471B2 (ja) * | 2006-07-06 | 2010-10-20 | 株式会社コーセー | 外用に適する組成物 |
| ITMI20072237A1 (it) | 2007-11-27 | 2009-05-28 | Sigea Srl | Esteri misti butirrico-formico di polisaccaridi acidi, loro preparazione ed uso come dermocosmetici |
| SI2679278T1 (en) * | 2008-11-20 | 2018-02-28 | Laboratori Derivati Organici S.P.A. | Dermatological compositions comprising heparan sulphate |
-
2009
- 2009-09-29 SI SI200931764T patent/SI2679278T1/en unknown
- 2009-09-29 PT PT97835227T patent/PT2346573E/pt unknown
- 2009-09-29 KR KR1020117013681A patent/KR101669528B1/ko active Active
- 2009-09-29 LT LTEP13159487.1T patent/LT2679278T/lt unknown
- 2009-09-29 PT PT131594871T patent/PT2679278T/pt unknown
- 2009-09-29 PL PL09783522T patent/PL2346573T3/pl unknown
- 2009-09-29 WO PCT/EP2009/062582 patent/WO2010057710A2/en not_active Ceased
- 2009-09-29 EP EP09783522.7A patent/EP2346573B1/en active Active
- 2009-09-29 EP EP13159487.1A patent/EP2679278B1/en active Active
- 2009-09-29 US US13/129,030 patent/US9440099B2/en active Active
- 2009-09-29 DK DK09783522.7T patent/DK2346573T3/da active
- 2009-09-29 ES ES13159487.1T patent/ES2650937T3/es active Active
- 2009-09-29 DK DK13159487.1T patent/DK2679278T3/en active
- 2009-09-29 PL PL13159487T patent/PL2679278T3/pl unknown
- 2009-09-29 HU HUE13159487A patent/HUE035362T2/en unknown
- 2009-09-29 HR HRP20140862AT patent/HRP20140862T1/hr unknown
- 2009-09-29 NO NO13159487A patent/NO2679278T3/no unknown
- 2009-09-29 SI SI200931013T patent/SI2346573T1/sl unknown
- 2009-09-29 JP JP2011536799A patent/JP2012509289A/ja active Pending
- 2009-09-29 ES ES09783522.7T patent/ES2507495T3/es active Active
-
2014
- 2014-06-06 JP JP2014117306A patent/JP6058588B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-04 US US15/228,150 patent/US20160338935A1/en not_active Abandoned
- 2016-12-05 JP JP2016235665A patent/JP2017043638A/ja active Pending
-
2017
- 2017-10-02 US US15/722,448 patent/US20180028427A1/en not_active Abandoned
- 2017-11-29 HR HRP20171861TT patent/HRP20171861T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2346573T3 (pl) | 2014-12-31 |
| HRP20171861T1 (hr) | 2018-01-26 |
| WO2010057710A2 (en) | 2010-05-27 |
| US20160338935A1 (en) | 2016-11-24 |
| JP6058588B2 (ja) | 2017-01-11 |
| EP2679278B1 (en) | 2017-09-06 |
| PL2679278T3 (pl) | 2018-02-28 |
| EP2346573A2 (en) | 2011-07-27 |
| ES2650937T3 (es) | 2018-01-23 |
| HRP20140862T1 (hr) | 2014-11-07 |
| LT2679278T (lt) | 2017-12-27 |
| JP2017043638A (ja) | 2017-03-02 |
| PT2679278T (pt) | 2017-12-13 |
| JP2014159488A (ja) | 2014-09-04 |
| KR20110086734A (ko) | 2011-07-29 |
| US20180028427A1 (en) | 2018-02-01 |
| US9440099B2 (en) | 2016-09-13 |
| NO2679278T3 (https=) | 2018-02-03 |
| DK2679278T3 (en) | 2017-12-11 |
| WO2010057710A3 (en) | 2011-06-03 |
| EP2679278A1 (en) | 2014-01-01 |
| SI2679278T1 (en) | 2018-02-28 |
| US20110288047A1 (en) | 2011-11-24 |
| PT2346573E (pt) | 2014-09-25 |
| ES2507495T3 (es) | 2014-10-15 |
| SI2346573T1 (sl) | 2014-10-30 |
| KR101669528B1 (ko) | 2016-10-26 |
| DK2346573T3 (da) | 2014-10-06 |
| WO2010057710A9 (en) | 2011-08-18 |
| JP2012509289A (ja) | 2012-04-19 |
| EP2346573B1 (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE035362T2 (en) | Dermatological preparations containing heparan sulfate | |
| JP2014159488A5 (https=) | ||
| DE3880577T2 (de) | Heparinderivate, verfahren zu deren herstellung und verwendung fuer pharmazeutische zwecke. | |
| RU2598552C2 (ru) | Сложные эфиры гиалуроновой кислоты, их получение и применение в дерматологии | |
| DE3750785T2 (de) | Oligosaccharide von Heparin mit einer Affinität für Faktoren von Zellwachstum. | |
| ES2848538T3 (es) | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible | |
| JP6000511B2 (ja) | 酸性多糖の酪酸−ギ酸混合エステル、ならびに肌用化粧品としてのその調製および使用 | |
| CN108542910B (zh) | 甘露葡萄糖醛酸寡糖的硫酸化衍生物在制备抗氧化药物中的应用 | |
| US20240091189A1 (en) | Methods for Assessing a Patient's Response to Treatment of a Neurodegenerative Disease with Deuterated Arachidonic Acid | |
| CN104395291A (zh) | N-乙基-4-羟基-1-甲基-5-(甲基(2,3,4,5,6-五羟基己基)氨基)-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺 | |
| Montoya et al. | Phototoxic effects of Heterophyllaea pustulata (Rubiaceae) | |
| Svanovsky et al. | The effect of molecular weight on the biodistribution of hyaluronic acid radiolabeled with111In after intravenous administration to rats | |
| Doleski et al. | Hepatic xanthine oxidase activity and purine nucleosides levels as physiological mediators to analyze a subcutaneous treatment with (PhSe) 2 in mice infected by Toxoplasma gondii | |
| CN115873144B (zh) | 一种乙酰化小分子透明质酸钠及其制备方法和应用 | |
| JP5786019B2 (ja) | 化粧品組成物 | |
| JP6778361B2 (ja) | フィラグリン遺伝子発現促進剤 | |
| CN107801402B (zh) | 用于诊断由微尘引起的皮肤损伤的组合物及包含高良姜素作为有效成分的组合物 | |
| SU876060A3 (ru) | Способ получени кортикоидов | |
| DE3410848C2 (de) | Verwendung von Flunarizin zur Behandlung von Tumoren | |
| TW200922605A (en) | Composition and treatment | |
| JP4663265B2 (ja) | 肌荒れ改善作用を有する皮膚外用剤 | |
| CN108218775A (zh) | 具有乙酰胆碱酯酶抑制活性吡唑化合物及其制备方法和应用 | |
| CN108084072A (zh) | 一种他卡西醇的异构体杂质py4及其制备方法和用途 | |
| NO140270B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktivt triamcinolonacetonid-4,4`-methylen-bis-(3-methoxy-2-nafthoat) |